NEW YORK (GenomeWeb) – The Alliance Global Group (AGBL) today announced an exclusive master distribution agreement for Fluxion Biosciences' IsoFlux and BioFlux systems in emerging markets in the Middle East, Asia, and Africa.
The IsoFlux Cell Separation System allows researchers to detect variants in circulating tumor cells by next-generation sequencing. The BioFlux System is for the introduction of flow conditions into research and drug discovery experiments to emulate the in vivo environment.
"We believe that Fluxion's products will offer our customers great tools for researching circulating tumor cell variants, and that it greatly complements our NGS product," Dina Amer, life sciences senior product manager at AGBL, said in a statement.
Based in South San Francisco, Calif., Fluxion provides tools for cell analysis. AGBL is a biotechnology firm based in Dubai, the United Arab Emirates that distributes research laboratory and diagnostic products
Financial and other terms of the agreement were not disclosed.